News from Paragon, Pantheon, Amgen and PharmaNet – People on the move

By Natalie Morrison

- Last updated on GMT

Related tags: Vice president, Pharmacology

Outsourcing-Pharma presents a round up of the latest appointments in the pharmaceutical outsourcing sector, will news from Paragon, Pantheon, Amgen and PharmaNet.

Paragon Bioservices​ have named Vadim Klyushnichenko​ as vice president. His experience in management spans 15 years, and includes the role of vice president of drug development at both Terapio and Coldstream Laboratories. Paragon CEO Marco Chacon said: “We feel that Vadim will be a great addition to Paragon's team as we continue to add personnel, double our process development and GMP manufacturing and add fill-and-finish capabilities to our facility.”

ReSearch Pharmaceutical Services (RPS) ​has added a host of new executives to its operation and senior management team.

Harris Koffer, President and COO, of the Phase II-IV clinical development solutions to the biopharmaceutical and medical CRO, said: "These additions will further strengthen our position as an innovator and leading provider of embedded and full-service clinical development solutions in support of our clients expanding global product development needs."

With more than 30 years of experience as an accomplished CIO and operations executive, John K. Davis​ will take the new chief information officer and executive vice president for clinical systems position.

Martine Dehlinger-Kremer​ is vice president of global regulatory affairs after serving in the same role at Theorem Clinical Research.

New VP of clinical programs and global site management Debra Marshall ​has over 30 years of healthcare and pharmaceutical industry management experience and most recent served as assistant VP of US global site management for Pfizer.

Lexy Kelley​, now MD as medical director of immunology development services brings experience in the design, implementation and medical oversight of clinical development programs for the treatment of Lupus as well as clinical research experience in hematology, infectious diseases, rheumatology and allergy.

And finally Peggy Doran​ as executive director, R&D Business Operations Management, comes with over 25 years of pharmaceutical industry experience as well as vendor relationship management and governance programs.

Pantheon ​has appointed former Research Triangle Foundation vice president Gary Shope​ to the newly created position of chief of staff. The new role focuses on critical internal activities related to the company's strategy and its implementation, sites and other real estate, human resources and communications with key internal and external audiences.

Former Amgen​ director of pharmacokinetics and drug metabolism George Scott ​has been appointed as VP, Bioanalytical Services at inVentiv​. Riaz Bandali, president of early stage development at inVentiv commented: “He has extensive knowledge of our clients' needs and is highly regarded in the industry for his scientific expertise and his business acumen.”

Joel Posener ​has joined PharmaNet​ as executive medical director of neuroscience. Before PharmaNet, Posener held roles at Wyeth as Senior Director, Neuroscience Medical Research and Senior Director, Early Development and Clinical Pharmacology. He also directed Phase II projects in a variety of psychiatric indications including cognitive impairment in schizophrenia, bipolar disorder and depression.

Shannon L.Yung​ has been drafted into patient recruitment and retention solutions company Acurian​’s clinical trial liason (CTL) team. A registered nurse with more than 12 years experience, Yung was most recently a clinical nurse liaison for the oncology business unit at Amgen,​ in Thousand Oaks. As part of the CTL team, Yung will specialize in localized and personalized service for oncology trial patient enrollment.

SCM Pharma​ has appointed a non-executive director to support its strategic development. Adam Sims ​will join the Northumberland-based company, which specialises in production services for pharmaceutical, biotech and medical device companies.

Related topics: Markets & Regulations

Related news

Show more

Follow us


View more